anti-TFPI
Pfizer’s HYMPAVZI Receives FDA Approval for Hemophilia A and B Treatment
HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor
Actionable Insights Powered by AI
HYMPAVZI, marstacimab-hncq, hemophilia A, hemophilia B, FDA approval, Pfizer, subcutaneous treatment, anti-TFPI inhibitor